Hydroxychloroquine, TTP, COVID-19, and SLE

Sookaromdee, Pathum; Wiwanitkit, Viroj

doi:10.4274/tjh.galenos.2021.2020.0770

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the first period of the COVID-19 pandemic, treatment with hydroxychloroquine (HCQ) was suggested as an inhibitor of SARS-CoV-2 in vitro, but recent studies involving SLE patients have demonstrated that the doses used in treatment of SLE are not protective against severe COVID-19 infection [5][6][7][8][9][10]. On the other hand glucocorticoids might increase the risk of hospitalisation and a subsequent severe outcome [11,12].…”

Section: Introductionmentioning

confidence: 99%

Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark

Cordtz

Kristensen

Dalgaard

et al. 2021

JCM

View full text Add to dashboard Cite

Background: Patients with systemic lupus erythematosus (SLE) have an increased risk of infections due to impaired immune functions, disease activity, and treatment. This study investigated the impact of having SLE on the incidence of hospitalisation with COVID-19 infection. Methods: This was a nationwide cohort study from Denmark between 1 March 2020 to 2 February 2021, based on the linkage of several nationwide registers. The adjusted incidence of COVID-19 hospitalisation was estimated for patients with SLE compared with the general population in Cox-regression models. Among SLE patients, the hazard ratio (HR) for hospitalisation was analysed as nested case-control study. Results: Sixteen of the 2533 SLE patients were hospitalised with COVID-19 infection. The age-sex adjusted rate per 1000 person years was 6.16 (95% CI 3.76–10.08) in SLE patients, and the corresponding hazard ratio was 2.54 (95% CI 1.55–4.16) compared with the matched general population group after adjustment for comorbidities. Among SLE patients, hydroxychloroquine treatment was associated with a HR for hospitalisation of 0.61 (95% CI 0.19–1.88), and 1.06 (95% CI 0.3–3.72) for glucocorticoid treatment. Conclusion: Patients with SLE were at increased risk of hospitalisation with COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark

Cordtz

Kristensen

Dalgaard

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

The impact of the COVID-19 pandemic on SLE

Zhao

et al. 2023

Modern Rheumatology

View full text Add to dashboard Cite

Little is known about the association between coronavirus disease 2019 [COVID-19] and autoimmune diseases, especially for systemic lupus erythematosus [SLE]. SLE patients meet with a throng of questions during the pandemic, including minimize the risk of infection, the complex pathological features and cytokine profiles, diagnosis and treatment, rational choice of drugs and vaccine, good nursing and psychological supervision, etc. In this study, we review and discuss the multifaceted effects of the COVID-19 pandemic on patients living with SLE using the available literatures. Cross-talk was existed in implicated inflammatory pathways/mechanisms between SLE and SARS-CoV-2 infection, and SARS-CoV-2 infection shares similarities with SLE in clinical characters and immuno-inflammatory responses. Current epidemiological data inadequate assess the risk and severity of COVID-19 in SLE. More evidences supported that HCQ and CQ unable prevent COVID-19. During the pandemic, patients with SLE had a higher rate of hospitalization. Vaccination helps to reduce the risk of infection. Several therapies for patients with SLE infected COVID-19 were discussed. The cases in the study can provide meaningful information for clinical diagnosis and management. Our mainly aim is to help the prevention and treatment of patients with SLE infected COVID-19.

show abstract

Hydroxychloroquine, TTP, COVID-19, and SLE

Cited by 2 publications

References 7 publications

Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark

Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark

The impact of the COVID-19 pandemic on SLE

Contact Info

Product

Resources

About